home / stock / mrus / mrus news

MRUS News and Press, Merus N.V. From 01/19/21

Stock Information
Company Name: Merus N.V.
Stock Symbol: MRUS
Market: NASDAQ
Website: merus.nl
Menu
MRUS MRUS Quote MRUS Short MRUS News MRUS Articles MRUS Message Board
Get MRUS Alerts

News, Short Squeeze, Breakout and More Instantly...
MRUS - Merus N.V. Announces Proposed Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® ...
MRUS - Lilly teams up with Merus to discover T-cell re-directing antibody therapies

Eli Lilly's (LLY) R&D group Loxo Oncology (LOXO) and Merus (MRUS) announce a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics platform along with the scientific and rational drug design expertise of Loxo Oncology (LOXO) at Lilly t...

MRUS - Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies PR Newswire INDIANAPOLIS and UTRECHT, The Netherlands , Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Li...

MRUS - Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced collaborations w...
MRUS - Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ant...

MRUS - Jaguar Health and Chimerix among healthcare gainers; Sarepta Therapeutics leads losers

Gainers: Chimerix (CMRX) +59%. Jaguar Health (JAGX) +36%. Medigus (MDGS) +23%. Merus (MRUS) +22%. SCWorx (WORX) +20%.Losers: Sarepta Therapeutics (SRPT) -50%. SOS (SOS) -42%. Neoleukin Therapeutics (NLTX) -15%. Bionano Genomics (BNGO) -14%. Solid Biosciences (SLDB) -12%. For furth...

MRUS - MARA, SOL, IDEX and JAGX among premarket gainers

Lion Group Holding (LGHL) +142%.SCWorx (WORX) +55%.Future FinTech Group (FTFT) +41%.Optical Cable Corporation (OCC) +29%.ZW Data Action Technologies (CNET) +29%.Jaguar Health (JAGX) +25%.Merus N.V. (MRUS) +24% after FDA grants Fast Track designation to it's Zenocutuzumab.Ideanomics ...
MRUS - SRPT, BNGO, WDFC and MRUS among after-hours movers

Gainers: [[OCC]] +40.5%. [[MRUS]] +27.2%. [[DRTT]] +22.2%. [[OEC]] +13.9%. [[WDFC]] +13.8%.Losers: [[SRPT]] -51.6%. [[SLDB]] -24.5%. [[BNGO]] -11.6%. [[UUU]] -9.7%. [[CERC]] -7.2%. For further details see: SRPT, BNGO, WDFC and MRUS among after-hours movers

MRUS - Merus' Zenocutuzumab wins FDA's fast track status

The FDA grants Fast Track Designation to Merus N.V.'s (MRUS) Zenocutuzumab ((Zeno)) for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions (NRG1+ cancers) that have progressed on standard of care therapy.Merus is currently enrolling patients into the ...

MRUS - Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™) for cancer, today announced that the U....
Previous 10 Next 10